Review Article
Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets
Table 3
Investigational monoclonal antibodies in MM.
| | Target molecule | mAb | Type | Clinical trials |
| | CD138 | Indatuximab ravtansine | ADC | Inda ± Rena ORR 78% vs 4% | | CD56 | Lorvotuzumab | ADC | Lorv+/Rd ORR 56% vs 7% | | CD40 | Dacetuzumab, lucatumumab | Humanized | Luc; 4% attained prolonged PR | | CD74 | Milatuzumab | Humanized | No objective responses | | BAFF | Tabalumab | Humanized | Bd + Taba; ORR 44% | | BCMA | GSK2857916 | ADC | MTD not determined | | GRP78 | PAT-SM6 | Humanized | MTD not determined | | IGF-1R | AVE1642 | Humanized | No objective responses | | ICAM-1 | BI-505 | Humanized | No objective responses | | CD26 | YS110 (huCD26mAb) | Humanized | Best responses 50% |
|
|
ADC, antibody-drug conjugate; Lena, lenalidomide; Inda, indatuximab ravatansine, Rd, lenalidomide plus dexamethasone; Lorv, lorvotuzumab; Luc, lucatumumab; PR, partial response; Bd, bortezomib + dexamethasone; Taba, tabalumab; MTD, maximum tolerated doses.
|
